Molecular Characterisation of Long-Acting Insulin Analogues in Comparison with Human Insulin, IGF-1 and Insulin X10

The influence of glucose-lowering therapies on cancer risk in type 2 diabetes

C. J. Currie, C Poole, E.A.M. Gale · Diabetologia · 2009 · 1.1K citations · Full text

Glucose-lowering Therapies, Diabetes Management, Oncology +7

Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use.

Peter Kurtzhals, L. Schäffer, Annette Sørensen et al. · Diabetes · 2000 · 734 citations · Full text

Mitogenic Potencies, Insulin Signaling, Metabolic Syndrome +21

Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study

Lars G. Hemkens, Ulrich Grouven, Ralf Bender et al. · Diabetologia · 2009 · 598 citations · Full text

Insulin/Insulin-like Growth Factor I Hybrid Receptors Have Different Biological Characteristics Depending on the Insulin Receptor Isoform Involved

Giuseppe Pandini, Francesco Frasca, Rossana Mineo et al. · Journal of Biological Chemistry · 2002 · 490 citations · Full text

Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden

Junmei Miao Jonasson, Rickard Ljung, Mats Talbäck et al. · Diabetologia · 2009 · 407 citations · Full text

Diabetes Management, Insulin Glargine Use, Insulin Management +8